In addition, Akt activity has been shown to be upregulated in alveolar epithelial type 2 (AE2) cells of IPF lungs, supporting the notion that targeting Akt might represent a therapeutic approach in HPS and IPF [52] (Figure 1). This evidence concerns the gene AKT1 and idiopathic pulmonary fibrosis.